Regulatory Oversight, Biden Administration, Food and Drug Administration (FDA)

FDA Announces Plans for Post-Market Chemical Review Program

Hogan Lovells on 5/21/2025

The U.S. Food and Drug Administration (FDA) recently announced plans to update its post-market food chemical review program. In its announcement, FDA explained that its forthcoming plans will take a proactive approach to...more

Recent Healthcare-Related Artificial Intelligence Developments

Sheppard Mullin Richter & Hampton LLP on 2/27/2024

AI is here to stay. The development and use of artificial intelligence (“AI”) is rapidly growing in the healthcare landscape with no signs of slowing down. From a governmental perspective, many federal agencies are embracing...more

HHS Proposes Rescheduling Cannabis to Schedule III – What It Means for the Industry

Troutman Pepper Locke on 9/5/2023

It has been widely reported and confirmed publicly that, on August 29, the U.S. Department of Health and Human Services (HHS) sent a letter to the Drug Enforcement Administration (DEA) recommending that cannabis be moved from...more

What’s on the Agenda? Laboratory Developed Tests Added to the Unified Regulatory Agenda Signals FDA Movement Toward New Regulatory...

Epstein Becker & Green on 6/30/2023

The Food and Drug Administration (“FDA” or “agency”) intends to issue a notice of proposed rulemaking in August 2023 that will “make explicit” that laboratory developed tests (LDTs) are devices under the federal Food, Drug,...more

Food and Beverage Litigation and Regulatory Update - January 2023

Shook, Hardy & Bacon L.L.P. on 1/9/2023

LEGISLATION, REGULATIONS & STANDARDS - Omnibus Spending Bill Includes Congressional Notes to FDA - President Biden has signed a spending bill that includes additional funding for the U.S. Food and Drug Administration (FDA)...more

Regulatory Oversight › Biden Administration › Food and Drug Administration (FDA)

FDA Announces Plans for Post-Market Chemical Review Program

Recent Healthcare-Related Artificial Intelligence Developments

HHS Proposes Rescheduling Cannabis to Schedule III – What It Means for the Industry

What’s on the Agenda? Laboratory Developed Tests Added to the Unified Regulatory Agenda Signals FDA Movement Toward New Regulatory...

Food and Beverage Litigation and Regulatory Update - January 2023

"My best business intelligence, in one easy email…"